ADUS vs ALHC

For growth investors, Alignment Healthcare, Inc.

(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus 23. 2% for Addus HomeCare Corporation (ADUS). Addus HomeCare Corporation (ADUS) offers the better valuation at 18. 5x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Addus HomeCare Corporation (ADUS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Addus HomeCare Corporation is actually cheaper at 14.

0x.

Over the past 5 years, Addus HomeCare Corporation (ADUS) delivered a total return of +2.

6%, compared to -27. 8% for Alignment Healthcare, Inc. (ALHC). Over 10 years, the gap is even starker: ADUS returned +427. 2% versus ALHC's +4. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Addus HomeCare Corporation (ADUS) is the lower-risk stock at 0.

58β versus Alignment Healthcare, Inc. 's 0. 75β — meaning ALHC is approximately 30% more volatile than ADUS relative to the S&P 500. On balance sheet safety, Addus HomeCare Corporation (ADUS) carries a lower debt/equity ratio of 19% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alignment Healthcare, Inc.

(ALHC) is pulling ahead at 46. 1% versus 23. 2% for Addus HomeCare Corporation (ADUS). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to 23. 2% for Addus HomeCare Corporation. Over a 3-year CAGR, ALHC leads at 40. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Addus HomeCare Corporation (ADUS) is the more profitable company, earning 6.

7% net margin versus -0. 0% for Alignment Healthcare, Inc. — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADUS leads at 9. 7% versus 0. 4% for ALHC. At the gross margin level — before operating expenses — ADUS leads at 32. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Addus HomeCare Corporation (ADUS) trades at 14.

0x forward P/E versus 140. 1x for Alignment Healthcare, Inc. — 126. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 9% to $24. 83.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

58), +427. 2% 10Y return). Both have compounded well over 10 years (ADUS: +427. 2%, ALHC: +4. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.